This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Earnings Preview: United Therapeutics (UTHR) Q1 Earnings Expected to Decline
by Zacks Equity Research
United Therapeutics (UTHR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
United Therapeutics (UTHR) Down 13% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
United Therapeutics (UTHR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Is iShares US SmallCap Equity Fac (SMLF) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for SMLF
Should iShares MSCI USA Small-Cap Min Vol Factor ETF (SMMV) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for SMMV
Should iShares MSCI USA Small-Cap Multifactor ETF (SMLF) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for SMLF
United Therapeutics (UTHR) Q4 Earnings & Sales Miss Estimates
by Zacks Equity Research
United Therapeutics' (UTHR) fourth-quarter earnings and sales miss estimates. Tyvaso sales continue to drive the company's top line.
United Therapeutics (UTHR) Q4 Earnings and Revenues Miss Estimates
by Zacks Equity Research
United Therapeutics (UTHR) delivered earnings and revenue surprises of -35.19% and 0.19%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Should You Buy United Therapeutics (UTHR) Ahead of Earnings?
by Zacks Equity Research
United Therapeutics (UTHR) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Analysts Estimate Pacira (PCRX) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Pacira (PCRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
by Zacks Equity Research
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
Strength Seen in Liquidia Technologies, Inc. (LQDA): Can Its 9.7% Jump Turn into More Strength?
by Zacks Equity Research
Liquidia Technologies, Inc. (LQDA) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
UTHR vs. ZTS: Which Stock Is the Better Value Option?
by Zacks Equity Research
UTHR vs. ZTS: Which Stock Is the Better Value Option?
After Plunging -5.18% in 4 Weeks, Here's Why the Trend Might Reverse for United Therapeutics (UTHR)
by Zacks Equity Research
United Therapeutics (UTHR) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Why You Should Hold Molina Healthcare (MOH) in Your Portfolio
by Zacks Equity Research
Molina Healthcare (MOH) remains well-poised for growth on the back of a growing customer base within its Government business. Acquisitions and cost-saving measures also aid the health insurer.
Should iShares S&P MidCap 400 Growth ETF (IJK) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for IJK
Encompass Health's (EHC) Plan Marks Entry in Rhode Island
by Zacks Equity Research
Encompass Health (EHC) aims to build a 50-bed inpatient rehabilitation hospital in Rhode Island and extend its advanced rehabilitative services suite across the Northeast.
Is iShares MSCI USA SmallCap Multifactor ETF (SMLF) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for SMLF
UTHR or ESALY: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
UTHR vs. ESALY: Which Stock Is the Better Value Option?
Centene (CNC) Wins Contract From DHCS to Serve Medi-Cal Members
by Zacks Equity Research
Centene's (CNC) California subsidiary receives a contract from the DHCS to better address the health requirements of the state's Medi-Cal members.
Best Momentum Stock to Buy for January 4th
by Zacks Equity Research
UTHR and AXON made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on January 4, 2023.
New Strong Buy Stocks for January 4th
by Zacks Equity Research
STAA, CASY, THRM, MP and UTHR have been added to the Zacks Rank #1 (Strong Buy) List on January 4 , 2023.
Should iShares MSCI USA SmallCap Min Vol Factor ETF (SMMV) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for SMMV
Should iShares MSCI USA SmallCap Multifactor ETF (SMLF) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for SMLF
The Zacks Analyst Blog Highlights United Therapeutics, Intra-Cellular Therapies, Immunocore Holdings and Eli Lilly
by Zacks Equity Research
United Therapeutics, Intra-Cellular Therapies, Immunocore Holdings and Eli Lilly are part of the Zacks top Analyst Blog.
3 Drug Stocks Most Wall Street Analysts Are Bullish About
by Ekta Bagri
Here we present three drug and biotech stocks, UTHR, ITCI and IMCR, which most analysts on Wall Street are optimistic about. These companies have upside potential for 2023 despite an uncertain macro environment.